Moonlight Therapeutics, a biotechnology company, has received a multi-million dollar clinical trial grant from the National Institutes of Health to evaluate its treatment, MOON101, for peanut allergy in peanut allergic children and adults.

ATLANTA, GEORGIA (PRWEB) JULY 10, 2023

Moonlight Therapeutics, Inc., a biotechnology company developing an intracutaneous treatment for food allergy, announced it has received a multi-million dollar Fast-Track small business clinical trial grant to evaluate its treatment, MOON101, for peanut allergy in peanut allergic children and adults. The clinical trial grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). Moonlight has already completed a pre-IND meeting with the FDA on the first-in-human clinical trial for MOON101.

Monlight Therapeutics logo

MOON101 uses Moonlight’s proprietary platform, a small, minimally invasive skin stamp, designed to break through the top-most layers of the skin barrier and deliver allergens to the skin’s immune cells in order to desensitize someone suffering from a food allergy. The dermal stamp is designed for at home self-administration. It is applied for only a few minutes and then removed. The approach has shown promising results in animal models of peanut and other allergies; data from these studies have been published in peer-reviewed journals.

This grant is the second small business grant the company has received from NIAID to develop MOON101 for the treatment of peanut allergy, bringing the company’s total non-dilutive funding to over $5 million. “This clinical trial grant represents further scientific validation of the company’s promising technology to address a large unmet need in the treatment of peanut and other food allergies,” said Samir Patel, Moonlight Therapeutics co-founder and CEO. “We were awarded this grant through a highly competitive review and it represents the meaningful progress we have made in advancing MOON101 towards the clinic.”

The clinical trial will be conducted in conjunction with several leading food allergy centers and clinical investigators in the United States. “There are over 6 million individuals in the United States alone with a peanut allergy and with only one FDA-approved therapy, there is still a large unmet need for patients and their families,” said Dr. Brian Vickery, who is the Director of the Food Allergy Center at Emory and Children’s Healthcare of Atlanta and serves as the lead clinical investigator on this grant. Dr. Vickery has been an investigator in food allergy clinical trials conducted at several stages of development including registration trials. “Clinical data from this grant will allow us to evaluate the effects of MOON101 directly on peanut allergic patients.”

“This award provides validation for the scientific approach Moonlight is taking and will facilitate the company’s entry into clinical trials,” added Dr. James Baker MD who is the founding Director of the Mary H. Weiser Food Allergy Center at University of Michigan and a former CEO of Food Allergy Research and Education (FARE), the national food allergy foundation.

Moonlight will be raising private funds to complement this award in order to accelerate the collection of the clinical data and development of MOON101.

About Moonlight Therapeutics

Moonlight Therapeutics is an early-stage biotechnology company based in Atlanta, Georgia. Moonlight is developing an intracutaneous allergen-specific immunotherapy platform for treating for food allergies. Food allergies are estimated to affect more than 30 million people in the United States. Moonlight has developed its proprietary platform, to break through the skin barrier and deliver allergens to immune cells in the top layer of the skin. This platform can be used to deliver individual or combinations of allergens to treat multiple allergies. This technology was invented at Texas Tech University and is supported by the Georgia Research Alliance. To learn more, visit  moonlighttx.com.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Moonlight’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Moonlight’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Moonlight undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: